LRMR - Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program May, 30 2024 06:23 PM Larimar Therapeutics Inc. 2024-05-30 18:23:09 ET More on Larimar Therapeutics Larimar stock rallies 24% on FDA removal of partial clinical hold Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics For further details see: Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program